Search hospitals

>

Illinois

>

Peru

Valley Radiation Oncology

Claim this profile

Peru, Illinois 61354

Global Leader in Breast Cancer

Global Leader in Lung Cancer

Conducts research for Breast cancer

Conducts research for Cancer

Conducts research for Pancreatic Cancer

242 reported clinical trials

2 medical researchers

Photo of Valley Radiation Oncology in PeruPhoto of Valley Radiation Oncology in Peru

Summary

Valley Radiation Oncology is a medical facility located in Peru, Illinois. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Cancer, Pancreatic Cancer and other specialties. Valley Radiation Oncology is involved with conducting 242 clinical trials across 441 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.

Area of expertise

1

Breast Cancer

Global Leader

Valley Radiation Oncology has run 53 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
ER positive
HER2 negative
2

Lung Cancer

Global Leader

Valley Radiation Oncology has run 46 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage II
Stage I

Top PIs

Clinical Trials running at Valley Radiation Oncology

Bladder Cancer

Lung Cancer

Prostate Cancer

Pancreatic Cancer

Colorectal Cancer

Breast Cancer

Ovarian Cancer

Breast cancer

Esophageal cancer

Cancer

Image of trial facility.

Eribulin + Chemotherapy

for Bladder Cancer

This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.

Recruiting

2 awards

Phase 3

Image of trial facility.

Shorter Duration Radiation Therapy

for Bladder Cancer

This phase III trial compares the effect of decreased number of radiation (ultra-hypofractionated) treatments to the usual radiation number of treatments (hypofractionation) with standard of care chemotherapy, with cisplatin, gemcitabine or mitomycin and 5-fluorouracil for the treatment of patients with muscle invasive bladder cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a short period of time. Ultra-hypofractionated radiation therapy delivers radiation over an even shorter period of time than hypofractionated radiation therapy. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Chemotherapy drugs, such as mitomycin-C and 5-fluorouracil (5-FU), work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ultra-hypofractionated radiation may be equally effective as hypofractionated therapy for patients with muscle invasive bladder cancer.

Recruiting

2 awards

Phase 3

7 criteria

Image of trial facility.

Blood Sample Collection

for Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.

Recruiting

1 award

N/A

9 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Valley Radiation Oncology?